CA2979812C - Isolated peptides and fragments thereof from fibrinogen for use as drugs, particularly in skin inflammatory diseases - Google Patents

Isolated peptides and fragments thereof from fibrinogen for use as drugs, particularly in skin inflammatory diseases Download PDF

Info

Publication number
CA2979812C
CA2979812C CA2979812A CA2979812A CA2979812C CA 2979812 C CA2979812 C CA 2979812C CA 2979812 A CA2979812 A CA 2979812A CA 2979812 A CA2979812 A CA 2979812A CA 2979812 C CA2979812 C CA 2979812C
Authority
CA
Canada
Prior art keywords
seq
acnes
fragment
fibrinogen
pos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2979812A
Other languages
English (en)
French (fr)
Other versions
CA2979812A1 (en
Inventor
Nicolas Dupin
Philippe GRANGE
Vincent Calvez
Joel Raingeaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Universite Paris Cite
Universite Paris Saclay
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Universite Paris Cite
Universite Paris Saclay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Gustave Roussy (IGR), Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Sorbonne Universite, Universite Paris Cite, Universite Paris Saclay filed Critical Centre National de la Recherche Scientifique CNRS
Publication of CA2979812A1 publication Critical patent/CA2979812A1/en
Application granted granted Critical
Publication of CA2979812C publication Critical patent/CA2979812C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2979812A 2015-03-20 2016-03-21 Isolated peptides and fragments thereof from fibrinogen for use as drugs, particularly in skin inflammatory diseases Active CA2979812C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305414.3 2015-03-20
EP15305414 2015-03-20
PCT/EP2016/056179 WO2016150926A1 (en) 2015-03-20 2016-03-21 Isolated peptides and fragments thereof from fibrinogen for use as drugs, particularly in skin inflammatory diseases

Publications (2)

Publication Number Publication Date
CA2979812A1 CA2979812A1 (en) 2016-09-29
CA2979812C true CA2979812C (en) 2023-08-29

Family

ID=52807757

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2979812A Active CA2979812C (en) 2015-03-20 2016-03-21 Isolated peptides and fragments thereof from fibrinogen for use as drugs, particularly in skin inflammatory diseases

Country Status (10)

Country Link
US (1) US10323078B2 (https=)
EP (1) EP3270950B1 (https=)
JP (1) JP6840086B2 (https=)
CN (1) CN107636011B (https=)
AU (1) AU2016236297B2 (https=)
BR (1) BR112017020008A8 (https=)
CA (1) CA2979812C (https=)
DK (1) DK3270950T3 (https=)
ES (1) ES2880795T3 (https=)
WO (1) WO2016150926A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12502424B2 (en) 2023-05-05 2025-12-23 Sanofi Pasteur Inc. Compositions for use in treatment of acne
CN117304303B (zh) * 2023-07-14 2024-07-05 杭州恩和生物科技有限公司 纤连蛋白截短片段、组合物及用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69034085T2 (de) * 1989-04-10 2004-05-27 Helix BioMedix, Inc., Bothell Lytsche und proliferative Peptide und deren Verwendung als Pharmaka und Phytopharmaka
US5639940A (en) * 1994-03-03 1997-06-17 Pharmaceutical Proteins Ltd. Production of fibrinogen in transgenic animals
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
CA2296792A1 (en) * 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
JP2003503425A (ja) * 1999-06-30 2003-01-28 リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 血栓性又は血栓塞栓性疾患のための診断的試験
EP1411964A4 (en) * 2001-07-06 2006-06-14 Oregon Health Science Universi PEPTIDES MODULATING BLOOD COAGULATION AND METHODS OF USE
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CA2523358A1 (en) * 2003-04-23 2004-11-04 Hansa Medical Ab Method for identifying an anti-streptococcal agent and its use for treating streptococcal infections
BRPI0617688A2 (pt) * 2005-10-21 2011-06-07 Hoffmann La Roche método para expressão recombinante de um polipeptìdeo
US20130280820A1 (en) * 2005-12-16 2013-10-24 Schering Corporation Biomarkers for psoriasis
WO2008019129A2 (en) * 2006-08-04 2008-02-14 Stb Lifesaving Technologies, Inc. Solid dressing for treating wounded tissue
EP2361930A3 (en) * 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
CN101618211A (zh) * 2008-07-03 2010-01-06 珠海联邦制药股份有限公司 一种乙肝多肽疫苗及其应用
CA2730030C (en) * 2008-07-09 2019-09-03 Profibrix Bv Recombinant fibrinogen
EP2352998A4 (en) 2008-11-07 2011-09-21 Centocor Ortho Biotech Inc MARKERS AND METHOD FOR THE STUDY AND TREATMENT OF LIGHT-SENSITIVELY LUPUS PATIENTS
EP4012714A1 (en) * 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
EP2927690B1 (en) * 2011-02-02 2022-10-26 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Anti-carbamylated protein antibodies and the risk for arthritis

Also Published As

Publication number Publication date
AU2016236297A1 (en) 2017-09-28
EP3270950B1 (en) 2021-04-21
JP2018512844A (ja) 2018-05-24
JP6840086B2 (ja) 2021-03-10
AU2016236297B2 (en) 2020-07-23
CN107636011A (zh) 2018-01-26
EP3270950A1 (en) 2018-01-24
BR112017020008A2 (pt) 2018-06-19
CA2979812A1 (en) 2016-09-29
ES2880795T3 (es) 2021-11-25
US10323078B2 (en) 2019-06-18
CN107636011B (zh) 2021-07-02
DK3270950T3 (da) 2021-06-07
US20180105574A1 (en) 2018-04-19
WO2016150926A1 (en) 2016-09-29
BR112017020008A8 (pt) 2023-05-02

Similar Documents

Publication Publication Date Title
US10980848B2 (en) Antimicrobial therapy
Li et al. OM‐LV20, a novel peptide from odorous frog skin, accelerates wound healing in vitro and in vivo
Lande et al. Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self‐DNA
Malkoski et al. Kappacin, a novel antibacterial peptide from bovine milk
Bastos et al. Human antimicrobial peptides in bodily fluids: current knowledge and therapeutic perspectives in the postantibiotic era
EP1151009B1 (en) Antimicrobial/endotoxin neutralizing polypeptide
Gebrim et al. Antitumor effects of snake venom chemically modified Lys49 phospholipase A2-like BthTX-I and a synthetic peptide derived from its C-terminal region
Edström Hägerwall et al. β-Microseminoprotein endows post coital seminal plasma with potent candidacidal activity by a calcium-and pH-dependent mechanism
Zheng et al. C5a/C5aR1 mediates IMQ‐induced psoriasiform skin inflammation by promoting IL‐17A production from γδ‐T cells
Rotllant et al. Generation, purification and functional characterization of three C3a anaphylatoxins in rainbow trout: role in leukocyte chemotaxis and respiratory burst
Hayakawa et al. Peptidomic analysis of human reflex tear fluid
CA2979812C (en) Isolated peptides and fragments thereof from fibrinogen for use as drugs, particularly in skin inflammatory diseases
Kim et al. Antimicrobial activity of antimicrobial peptide LPcin-YK3 derived from bovine lactophoricin
Barberio et al. A low molecular weight protein with antimicrobial activity in the cutaneous ‘venom’of the yellow-bellied toad (Bombina variegata pachypus)
Fu et al. The anti-myotoxic effects and mechanisms of Sinonatrix annularis serum and a novel plasma metalloproteinase inhibitor towards Deinagkistrodon acutus envenomation
Moreira et al. Frontoxins, three-finger toxins from Micrurus frontalis venom, decrease miniature endplate potential amplitude at frog neuromuscular junction
Suarez et al. An extracellular matrix, calmodulin-binding protein from Dictyostelium with EGF-like repeats that enhance cell motility
Xia et al. Customized screening of ACE2 regulatory peptides from oyster to mitigate LPS-induced acute lung injury based on SPR technology
CN118773176B (zh) 一种蛇毒类凝血酶蛋白及其制备方法与应用
Bame et al. Characterization of a novel intracellular heparanase that has a FERM domain
Hagerwall et al. b-Microseminoprotein Endows Post Coital Seminal Plasma with Potent Candidacidal Activity by a Calcium-and pH-Dependent Mechanism
Mou et al. Pro-IL-1β activates NF-κB independently of maturation
Davenport Investigating how post translational modifications of p97 affect its function and regulation during DNA synthesis
Moos et al. Purification and stability characterization of a cell regulatory sialoglgycopeptide inhibitor
Amici et al. Control of RNA and protein synthesis in phytohemagglutinin-stimulated human lymphocytes by chromatin peptides from calf thymus

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210319

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250226

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250226

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250226

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260223

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260223